EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy

Anıl Cengiz iD, Calvin C Wu iD, Sean D Lawley iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anıl Cengiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To discover alternative dosing regimens of incretin mimetics that simultaneously reduce costs and maintain weight loss efficacy. As a secondary objective, we used our results to explore how allocating a limited incretin mimetics budget could affect public health on a national scale. Materials and Methods We used mathematical modelling and simulation of semaglutide and tirzepatide to investigate dosing regimens which have not yet been studied clinically. For semaglutide, we used a recent pharmacokinetic (PK) and pharmacodynamic (PD) model. For tirzepatide, we used a recent PK model and modelled PD by reparameterizing the semaglutide PD model to fit tirzepatide clinical data.

Results

Reducing dose frequency does not commensurately reduce weight loss. For example, merely switching from one dose per week (q1wk) to one dose every 2 weeks (q2wk) maintains roughly 75% of the weight loss. Furthermore, if the decrease in dose frequency involves an appropriate increase in dose size, then approximately 100% of the weight loss is maintained. In addition, we compared offering incretin mimetics to (1) a fraction of obese US adults with q1wk dosing versus (2) twice as many obese US adults with q2wk dosing. Though scenarios (1) and (2) require the same budget, our analysis suggests that (2) reduces national obesity and mortality to a much greater degree.

Conclusion

Our study highlights the potential utility of alternative dosing regimens of incretin mimetics. Compared with standard once‐weekly dosing, costs can be halved and weight loss maintained. These cost‐saving results have implications for patients, physicians, insurers, and governments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesWeight LossGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2ObesityHypoglycemic AgentsIncretinsAnti-Obesity AgentsHumansTirzepatideDrug Administration ScheduleDrug CostsCost-Benefit AnalysisTreatment OutcomeDose-Response Relationship, DrugGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GIPGLP‐1cost‐effectivenesspharmacodynamicspharmacokineticssemaglutide

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideHypoglycemic AgentsIncretinsAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Mathematics, University of Utah, Salt Lake City, Utah, USA.
  • Tono Health, Brooklyn, New York, USA.

ORCID-Profile: Anıl Cengiz, Calvin C Wu, Sean D Lawley

Förderung

  • National Science Foundation

Zitieren

APA

Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16229

Vancouver

Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16229

BibTeX
@article{Cengiz2025,
  author = {Cengiz, Anıl and Wu, Calvin C and Lawley, Sean D},
  title = {Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16229}
}
Kostenlos starten →